Interplay of Oct4 with Sox2 and Sox17: a molecular switch from stem cell pluripotency to specifying a cardiac fate by Stefanovic, Sonia et al.
The Rockefeller University Press    $30.00
J. Cell Biol. Vol. 186 No. 5  665–673
www.jcb.org/cgi/doi/10.1083/jcb.200901040 JCB 665
JCB: REPORT
N. Abboud and S. Désilets contributed equally to this paper.
Correspondence to Michel Pucéat: michel.puceat@inserm.fr
Abbreviations used in this paper: CM, conditioned medium; cTnT, cardiac tro-
ponin T; EB, embryoid body; ESC, embryonic stem cell; HCC, high content cell; 
HESC, human ESC; iPSC, induced pluripotent stem cell; Oct4-iA-OEC, Oct4-
iA–overexpressing cells; p, promoter; RT-Q-PCR, real-time quantitative PCR;   
TF, transcription factor.
Introduction
Embryonic stem cells (ESCs), derived from the inner cell mass of 
the blastocyst or induced pluripotent stem cells (iPSCs) derived 
from reprogrammed somatic cells retain the ability to self-renew 
in culture and the potential to differentiate into any cell lineage. 
The ESC-specific protein, Oct4, is one of the most ancient tran-
scription factors (TFs) and is expressed very early during embry-
onic development (Smith, 1991). In mouse ESCs, together with 
Sox2 and Nanog, Oct4 cooperatively maintains pluripotency 
through a tightly regulated transcriptional loop (Loh et al., 2006; 
Niwa, 2007). However, a new function of this TF has recently 
emerged in the process of cell lineage determination. In fact, the 
level of Oct4 in ESCs determines its dual function (Niwa et al., 
2000). The mechanism of that process remained unknown. We 
demonstrated in vitro and in vivo a gene dosage-dependent 
function of Oct4, driving the ESC or the epiblast toward a meso-
dermal cardiogenic fate (Zeineddine et al., 2006).
However, the genetic and epigenetic mechanisms under-
lying the dual function of Oct4, maintaining pluripotency or 
inducing lineage progression, has remained puzzling. Further-
more, whether this concept applies to human pluripotent cells 
is also questionable.
Results and discussion
We chose the cardiac lineage, determined as early as within the 
epiblast (Tam and Schoenwolf, 1999), to analyze the dual func-
tion of Oct4. First, we tested whether BMP2-induced cardiac 
commitment and differentiation of HESC (Tomescot et al., 
2007) was associated with modulation of Oct4. Expression of 
both human Oct4 isoforms, Oct4-iA, maintaining cell pluri-
potency (Lee et al., 2006), and Oct4-iB of still unknown function, 
was monitored by real-time quantitative PCR (RT-Q-PCR). 
Oct4-iA was up-regulated threefold in response to BMP2. Expres-
sion of Oct4-iB remained unchanged (Fig. 1 A). We then used a 
HESC line harboring a reporter gene (HUES-9 pOct4/GFP, 
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ct4  exerts  a  dose-dependent  dual  action,  as 
both a gatekeeper for stem cell pluripotency 
and  in  driving  cells  toward  specific  lineages. 
Here, we identify the molecular mechanism underlying 
this dual function. BMP2- or transgene-induced Oct4 up-
regulation drives human embryonic and induced pluri-
potent stem cells to become cardiac progenitors. When 
embryonic stem cell pluripotency is achieved, Oct4 switches 
from the Sox2 to the Sox17 promoter. This switch allows 
the cells to turn off the pluripotency Oct4-Sox2 loop and 
to turn on the Sox17 promoter. This powerful process gen-
erates a subset of endoderm-expressing Sox17 and Hex, 
both regulators of paracrine signals for cardiogenesis (i.e., 
Wnt, BMP2) released into the medium surrounding colo-
nies of embryonic stem cells. Our data thus reveal a novel 
molecular  Oct4-  and  Sox17-mediated  mechanism  that 
disrupts  the  stem  cell  microenvironment  favoring  pluri-
potency to provide a novel paracrine endodermal environ-
ment in which cell lineage is determined and commits the 
cells to a cardiogenic fate.
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Sox2 as an Oct4 target, namely Sox17, recently reported as 
essential for early cardiogenesis (Liu et al., 2007), was expressed 
in Oct4-iA-OEC (Fig. 1, F and G). We therefore tested the pres-
ence of Oct4 on Sox17p. ChIP assays designed to pull down 
Oct4-bound chromatin revealed that BMP2 led to a 10-fold 
decrease in enrichment of DNA fragments containing the Sox2 
distal enhancer (Chew et al., 2005) and a 300-fold increase in the 
enrichment of DNA fragments containing a region of the Sox17p 
within the 700-bp upstream of the transcription start site (Fig. 2, 
A and B). This result obtained in the HUES-24 line was con-
firmed in two other HESC lines (H9.2 and I4). This was accom-
panied with induction of Sox17 in BMP2-treated cells (Fig. 2 B, 
right inset). Oct4-iA-OEC featured a loss in Oct4-iA binding 
Sox2 DNA including the distal enhancer and a gain in binding 
Sox17p (Fig. 2, C and D). In line with these data, ChIP from 
Oct4-iA-OEC using anti-modified-H3 antibodies revealed sig-
nificant changes in methylation and acetylation of H3 associated 
with both Sox2 and Sox17 enhancer and promoter, respec-
tively, when compared with mock cells (i.e., GFP nucleofected). 
Although the ratio of methylations of K4 versus that of K27 of 
H3, as well as acetylation of H3K9 associated with Sox2 distal 
enhancer was decreased, these were increased for the Sox17p. 
This pointed to repression of Sox2 and activation of Sox17p, re-
spectively (Fig. 2 E). Furthermore, the Oct4/Sox2 interaction in 
control was lost upon up-regulation of Oct4-iA (Fig. 2 F). These 
transcriptional and epigenetic events led to Sox17 expression in 
BMP2-stimulated HESC (Fig. 2 G). A similar effect was ob-
served in Oct4-iA-OEC (Fig. 1 G). To gain more insight into the 
molecular mechanism of the switch of Oct4-iA from the Sox2p 
to the Sox17p, we manipulated the level of expression of Sox2 in 
Oct4-iA-OEC, surmising that a stoichiometric competition 
occurs between Sox2 and Sox17. A displacement of Oct4/Sox2 
complex on Sox2 distal enhancer would permit Oct4 binding to 
Sox17p, turning on the gene and the protein, which would   
reinforce Sox17 expression by forming an Oct4/Sox17 complex on 
its promoter. When Sox2 was up-regulated in cells nucleofected 
with the cDNA (Fig. S1 D), the gain in enrichment of Oct4-iA on 
the Sox17p was lost. When Sox2 was down-regulated using a 
shRNA (Chew et al., 2005) (Fig. S1, D and E), Oct4-iA binding 
to the Sox17p was dramatically increased (Fig. 2 H). We next 
looked for Oct4–Sox17 interaction in END-2 cells, an endo-
dermal cell line expressing Sox17 (Mummery et al., 1991). Using 
coimmunoprecipitation after overexpression of Oct4-iA in this 
cell line, we found that Sox17 binds Oct4 (Fig. 2 I). Altogether, 
our findings point to Sox17, a novel target of Oct4 also interact-
ing with it, to compete with Sox2 to switch HESC from a pluri-
potent toward an endodermal/mesodermal fate. To clarify whether 
Sox17 accounts for the switch of HESC from pluripotency to 
mesodermal and cardiac commitment of ESC, we used a shRNA 
approach. Sox17 ShRNA was nucleofected in HESC together 
with Oct4-iA cDNA. Sox17 mRNA was then reduced in the pres-
ence of an increased level of Oct4. The protein was also three 
times less induced by Oct4 overexpression (Fig. S1 F). The 
amount of Sox17 upon Oct4-iA up-regulation was thus too lim-
ited to significantly trigger cardiogenesis (Fig. 3 A). Similarly, 
BMP2, which induces Sox17 together with mesodermal and car-
diac genes, could no longer induce these genes in the presence of 
Oct4p driving EGFP) (Fig. 1 B, inset) to investigate BMP2-
mediated regulation of the Oct4p. First, to ensure that GFP was 
under the tight control of the Oct4p, the HUES-9 pOct4/GFP 
cell line was nucleofected with COUP-TFI, a repressor of Oct4 
(Ben-Shushan et al., 1995). GFP was switched off in cells   
expressing COUP-TFI, as shown by poor GFP distribution 
within colonies when compared with a fully green mock colony 
(Fig. S1 A). Furthermore, overexpression of Oct4-iA in the 
HUES-9 pOct4/GFP line increased GFP expression as ex-
pected from regulation of Oct4p by its own protein (Fig. S1 B). 
Stimulation of this line with BMP2 up-regulated GFP mRNAs 
(Fig. 1 B) and FACS revealed a 70% increase in the highly pos-
itive GFP population (Fig. 1 C).
To investigate whether a rise in Oct4-iA induces loss in cell 
pluripotency and promotes cell lineage specification, HESCs 
were nucleofected with Oct4-iA, or EGFP cDNA (mock cells). 
Cells were cultured for 4 d with FGF2. Oct4-iA-OEC (35 times), 
twofold more protein (Fig. 1 E, inset), did not change expression 
of Oct4-iB (Fig. 1 E). Indeed, only the 48-kD (Oct4-iA), but not 
the 35-kD band (Oct4-iB), was increased (Fig. 1 E, inset). SSEA-1 
was first used as an early marker of HESC loss of pluripotency 
(Hoffman and Carpenter, 2005). Less than 1% of mock cells 
(EGFP  nucleofected)  but  68%  of  Oct4-nucleofected  cells   
expressed SSEA-1 (Fig. 1 D). This percentage (68%), normalized 
to the one of cell nucleofection assessed by scoring GFP
+ cells 
(42%) (Fig. 1 D, inset), suggests that Oct4-iA-OEC as well   
as neighboring cells had entered a differentiation program. To   
examine which lineage was induced by Oct4, gene expression was 
monitored by Q-PCR. Oct4-iA-OEC expressed both mesodermal 
(Brachyury, Tbx6) and cardiac (Mesp1/2, Tbx20, Tbx5, Mef2C, 
Nkx2.5, cardiac -actin) markers (Fig. 1 E). Endodermal genes 
Hex and Sox17 were also switched on by Oct4-iA (Fig. 1 F). 
Furthermore, the corresponding proteins Sox17, Nkx2.5, and 
Mef2c were present (Fig. 1 G). High content cell (HCC) imaging 
assay allowed us to monitor more than 2,500 cells and revealed 
that 48% of cells expressed Sox17, indicating that all nucleo-
fected cells expressed the protein (when normalized to percent-
age of Oct4-iA nucleofection 42%, Fig. 1 D). Up to 20% (i,e., 
48% of nucleofected cells) expressed Mef2c, and 31% (74% of 
nucleofected cells) Nkx2.5 (Fig. 1 G). Very low expressions of 
the hematopoietic CD45, of the endothelial CD31, CD34 mark-
ers were detected (Fig. S1 C). Thus, PCR, immunofluorescence, 
and FACS data demonstrate that up-regulation of Oct4iA forces 
HESC to exit pluripotency to adopt a cardiovascular fate.   
Furthermore, the cardiogenic action of Oct4-iA was translated into 
a full cardiac differentiation program. While mock-nucleofected 
cells gave rise to cardiomyocytes expressing actinin and cardiac 
troponin T (cTnT), the later proteins were not yet organized 
in sarcomeric units 4 wk after embryoid body (EB) formation. 
In contrast, EBs generated from Oct4-iA-OEC featured 3.1 ± 0.2 
(n = 4) as many cTnT
+ and actinin
+ myocytes as in mock EBs, as 
assessed by measuring the anti-cTnT and anti-actinin fluorescent 
areas within whole EBs. Furthermore, the cardiomyocytes were 
assembled in strands and featured organized and adult-size sar-
comeres (2 µm) (Fig. 1 H). Next, we hypothesized that, to trigger 
specification to a cell lineage, increased Oct4 should disrupt the 
Sox2/Oct4 pluripotency loop. A potential candidate to replace 667 OCT4-INDUCED EARLY CARDIOGENESIS • Stefanovic et al.
Figure 1.  Overexpression of Oct4-iA induces cardiogenesis. HUES-24 (A) or HUES-9 pOct4/GFP (B) control or treated for 48 h with BMP2. (A) Oct4 
isoforms Q-PCR. (B) Q-PCR of GFP cDNA (n = 2–3). (C) GFP FACS in HUES-9 pOct4/GFP cells (top) nontreated (left) or treated (right) with BMP2.   
(D–F) Cells nucleofected with Oct4-iA or pCMV-GFP and cultured for 4 d. (D) FACS of GFP (inset = nucleofection efficiency) and SSEA-1 in mock cells 
(pcDNA backbone, left) and Oct4-iA-OEC (right). (E) Q-PCR of induced genes. (F) Q-PCR of Sox17 and Hex (amplicons on gel) (means ± SEM [n = 3–6] 
normalized to huGAPDH). *, Statistically significant (P ≤ 0.01). (G) Immunofluorescence of anti-Sox17, -Mef2c, and -Nkx2.5 of Oct4-iA OEC scanned by 
an arrayscan. Bars, 20 µm. (H) Immunofluorescence of anti-sarcomeric actinin and anti-cTnT of d-30 EBs generated from mock or Oct4-iA OECs.JCB • VOLUME 186 • NUMBER 5 • 2009   668
silencing), the Sox17p was no longer occupied by Oct4-iA   
(Fig. 3 B). Thus, collectively, these ChIP experiments (Figs. 2 and 3) 
showed the occupancy of Sox17p by Oct4. They further revealed 
Sox17 ShRNA (Fig. S1 G). However, Sox17 shRNA did not pre-
vent the loss of Sox2 DNA elements bound to Oct4-iA when 
overexpressed. Interestingly, under the same condition (i.e., Sox17 
Figure 2.  Oct4 interaction with Sox17 promoter and protein at the expense of Sox2. Ctrl HESC or treated for 48 h with BMP2, and used for anti-Oct4 
ChIP. Sox2 distal enhancer (A, pSox2) or Sox17p (B, pSox17) were amplified in RT-Q-PCR (insets = products on gel). (B, right inset) RT-Q-PCR for Sox17 
in cells treated or not with BMP2. (C and D) anti-Oct4 ChIP in Oct4-iA-OECs. pSox2 or pSox17 was amplified in Q-PCR (n = 3, means ± SEM). (E) Anti-
H3trimeK4, -H3trimeK27 and -H3acetylK9 ChIP in Oct4-iA-OECs. pSoxs were amplified in Q-PCR. Results are expressed as enrichment (H3AcK9) or as 
a ratio of enrichment (K4/K27). Data are normalized to inputs and to controls (chromatin from GFP-nucleofected cells) from two experiments (median ± 
errors). (F) Anti-Sox2 Western blots from Ctrl or Oct4-iA-OEC chromatin. (G) Immunofluorescence of anti-Sox17 and DAPI in Ctrl or BMP2-stimulated HESC. 
(H) Anti-Oct4 ChIP analysis of pSox17. Cells were nucleofected with GFP cDNA (Ctrl) or Oct4-iA cDNA alone or together with Sox2 cDNA or Sox2 ShRNA 
before ChIP. Q-PCR of pSox17 (gel of amplicons on the left). The enrichment in ShRNASox2
+ Oct4-OEC was normalized to the one of Oct4-iA-OECs (set 
to 1). Results are expressed as the median ± errors from two experiments. (I) END-2 cells expressing Sox17 were nucleofected with Oct4-iA and cultured 
for 2 d. Immunoprecipitation of anti-Oct4 and Western blot of anti-Sox17. END-2 whole-cell lysate was run as a positive control.669 OCT4-INDUCED EARLY CARDIOGENESIS • Stefanovic et al.
to induce cardiogenesis. CM from Oct4-iA-OEC triggers in wild-
type HESC expression of Brachyury, Mesp1/2, Tbx20, Tbx5, 
Tbx6, Nkx2.5, and cardiac -actin, as well as Oct4-iA (Fig. 4 A). 
CM from cells overexpressing GFP used as a control did not 
show any gene induction. Furthermore, CM from Oct4-iA-OEC 
applied to wild-type cells triggered a switch of Oct4-iA binding 
from the Sox2 distal enhancer to the Sox17p (Fig. 4 B). We also 
mixed in the same well HUES-9 pOct4/GFP cells nucleofected 
with Oct4-iA cDNA with mock cells at different ratios (0:1, 1:1, 
3:1, 9:1, respectively). After 4 d of co-culture, mock cell colonies 
were dissected out and used in real-time PCR. Expression of 
Tbx6 Mesp1, Isl1, Nkx2.5, Tbx5 was significantly induced in 
mock cells when they were mixed with at least three times as 
many Oct4-iA-OE HUES-9 pOct4/GFP cells as mock cells (3:1 
ratio) (Fig. S2 A). In another set of experiments, mixed cells 
were fixed and stained with an anti-Nkx2.5 antibody. These ex-
periments showed that Nkx2.5
+ cells were mainly mock HESC 
neighboring GFP
+ cells (Fig. S2 B), further confirming that 
Oct4-iA-OEC exert their cardiogenic function through secretion 
of cardiogenic factors. We hypothesized that BMP2 or/and Wnt, 
both direct or indirect targets of Sox17/Hex pathway, as well as 
Nodal, a Sox17 inducer, might be cardiogenic candidates released 
by OctiA- and Sox17-OEC. Thus, HESC were nucleofected with 
Oct4-iA cDNA and then cultured for 4 d in the absence or in 
the presence of 150 ng/ml Dipkopf (DKK), 100 ng/ml Noggin, or 
10 ng/ml Lefty to prevent Wnt, BMP2, or Nodal signaling, 
respectively. Fig. 4 C shows that both DKK and Noggin, but not 
Lefty,  prevented  Oct4-iA–induced  expression  of  Brachyury, 
Mesp, Tbx20, Tbx5, Tbx6, and Nkx2.5. Challenging HESC with 
BMP2 (10 ng/ml) together with Wnt3a (50 ng/ml) significantly 
improved the effect of BMP2 on early cardiac gene expression as 
well as on BMP2 and Wnt3a expression (Fig. S2 C). In line with 
these data, Oct4-iA-OEC expressed BMP2 and Wnt3a (Fig. 4 D). 
Thus, BMP2 and Wnt3a are the cardiogenic factors released by 
Oct4 induced Sox17
+ cells. Four other findings confirmed this 
claim. First, phosphorylated Smad recognized by an anti- 
phosphoSmad1,5,8 antibody was barely detectable in mock cells 
cultured alone, but observed into nuclei of Oct4-iA-OEC in wells 
including 50% (i.e., nucleofection efficiency) of Oct4-iA-OEC 
and 50% of non-nucleofected cells (Fig. S3 B). Second, anti-
Smad4 ChIP experiments revealed a binding of Smad to both the 
Nkx2.5 and Tbx6 promoters, two targets of BMP2 (Fig. S3 A) in 
Oct4-iA-OEC. Third, Wnt3a signaling pathway was activated in 
Oct4-iA-OEC, as visualized by nuclear localization of -catenin 
in contrast to the membrane staining observed in mock cells 
(Fig. S3 B). Finally, both anti-BMP2 and anti-Wnt3a antibodies 
added for 2 d in the medium of Oct4-iA-OEC prevented expres-
sion of genes marking the mesoderm (Tbx6), the cardiogenic 
mesoderm (Mesp1), and cardiac progenitors (Tbx5) (unpublished 
data). To further investigate whether cells expressing Sox17 
exerted their cardiogenic action through an autocrine and/or 
paracrine mechanism, HUES-9-pOct4/GFP cells were plated in 
microwells and stimulated for 4 d with BMP2. Cells expressing 
GFP were stained for Sox17 and Mesp1/2, the earliest cardiac 
marker. Cells not challenged with BMP2 did not express Sox17 
or Mesp1/2 (Fig. 4 E, top). Cells challenged with BMP2 expressed 
both Sox17 and Mesp1/2. Careful observation of cells revealed 
a predominance of K4 over K27 methylations, and an increase in 
K9 acetylation on H3 in the vicinity of the promoter, thus favor-
ing an active chromatin state. This leads to gene and protein 
expression. The opposite scenario occurs on the Sox2 distal en-
hancer (loss of Oct4 occupancy of the enhancer, increase in K27 
methylation, and a decrease in K9 acetylation of H3). Manipulat-
ing the levels of Sox2 and Sox17 further pointed to a competition 
between both Soxs as shown by the capability of Oct4 to form a 
complex with Sox17. We can further surmise that the Oct4/Sox2 
ratio is instrumental in creating various complexes with specific 
Sox proteins and/or DNA elements. At a normal level of Oct4 or 
Oct4/Sox2 ratio, it targets the Oct4–Sox2 enhancer, maintaining 
the transcriptional Oct4/Sox2/Nanog loop and thus cell pluri-
potency. At a higher Oct4 level or at a low level of Sox2, the POU 
factor targets the Sox17p triggering expression of the protein, 
forming a more stabilized Oct4/Sox17 complex on the Sox17p. 
This mechanism drives the cells toward specific endo/mesodermal 
fates. Sox17 is known to target genes encoding cardiogenic   
factors such as Wnts (Zorn et al., 1999). Wnt is also a trigger of 
BMP2 (Kasai et al., 2005). To test whether Oct4-iA and Sox17 
operate in a cell non-autonomous manner, the conditioned   
medium (CM) from Oct4-iA-OEC was collected to test its potential 
Figure  3.  Sox17  mediates  Oct4-triggered  cardiogenic  commitment  of 
HESC. Oct4-iA cDNA alone or together with Sox17 ShRNA was nucleo-
fected in HESC (A) Q-PCR of genes (n = 3). (B) Anti-Oct4ChIP-Q-PCR analy-
sis of Sox2 distal enhancer and Sox17p (n = 3, mean ± SEM).JCB • VOLUME 186 • NUMBER 5 • 2009   670
Figure 4.  Overexpression of Oct4-iA induces secretion of paracrine factors. (A) Q-PCR of genes (n = 3–5). (B) Anti-Oct4 ChIP analysis of Sox2 distal 
enhancer and Sox17p (pSox) in wild-type HESC treated for 4 d with CM of Oct4-iA-OEC. CM from GFP-nucleofected mock cells was used as control 
(experiment in duplicate). (C) HESC nucleofected with Oct4-iA or GFP (mock cells) and cultured for 4 d in the absence or presence of DKK, Noggin, or 
Lefty. (D) Q-PCR of BMP2 and Wnt3a in Oct4iA-OEC. (E) anti-Sox17 and -Mesp2 immunofluorescence of Ctrl and BMP2-treated HUES-9 pOct4/GFP 
cells. (F) Venn diagram for the number of cells positive for GFP, Sox17, and Mesp2 alone or together. Ctrl or BMP2-challenged HUES-9 pOct4/GFP cells 
in 96-well plates were stained with anti-Sox17 and -Mesp2 antibodies. Numbers in the diagram indicate the total number of cells and the percentage.   
*, Significantly different from control (P ≤ 0.001).671 OCT4-INDUCED EARLY CARDIOGENESIS • Stefanovic et al.
Our  data  thus  revealed  a  novel  Oct4/Sox17-mediated   
molecular mechanism that disrupts the microenvironment that 
favors cell pluripotency and prevents differentiation, to provide 
a novel paracrine environment more prone to commit the cells 
toward a cardiac lineage. iPSC are derived from somatic cells 
reprogrammed using Oct4, Sox2, Nanog, and Lin28 or Myc 
(Takahashi et al., 2007). We wondered whether manipulating the 
Oct4-iA level in such cells could also drive them through the 
Sox2/Sox17 switch toward a cardiogenic fate. Thus, iPSCs were 
nucleofected  with  Oct4-iA  cDNA  and  both  gene  expression   
and Sox17p occupancy were monitored by Q-PCR. Fig. S3 C shows 
that 5 d after nucleofection, iPSC expressing 10 times more 
Oct4-iA mRNA than GFP nucleofected cells changed of mor-
phology, displaying more flat and irregular colonies in comparison 
with compact colonies in mock cells expressing GFP. These cells 
expressed mesodermal and cardiac markers including Brachyury, 
Mesp1/2, Tbx20, Tbx5, and Nkx2.5, as well as Sox17 (Fig. S3 D). 
Oct4-iA switched from the Sox2 to the Sox17p (Fig. S3 E). 
This was associated with up-regulation of Sox17 (Fig. S3 D, inset) 
and of both Wnt3a and BMP2 mRNAs (Fig. S3 F).
Thus, we have found a novel molecular and cellular circuit 
in which Oct4 and Sox17 work in combination to drive human 
pluripotent stem cells toward an endodermal or mesendodermal 
fate, and in turn toward the fate of cardiac progenitors. This cir-
cuit is functional within an ESC colony or “niche”, BMP2 acting 
first in cells surrounding the colony, likely generating a gradient 
from the outer to the inner part of colonies rather secreting fac-
tors such as GDF3 maintaining a basal level of Oct4 and cell 
pluripotency (Peerani et al., 2007). Then, mesendo/endodermal 
Sox17
+ cells amplify the differentiation process by secreting   
cardiogenic factors (i.e., Wnt3a, BMP2), further acting on the colo-
nies to direct the cells toward a cardiogenic fate (Fig. 5). This 
molecular and cellular circuitry is likely to occur during the pro-
cess of somatic cell reprogramming using Oct4 as the main re-
programming inducer, pointing to the importance of an accurate 
Oct4/Sox2 dosage in these experiments. Oct4 dosage within the 
nucleus is thus crucial to build specific bridges between different 
(i.e., Sox2 or Sox17) chromatin domains, resulting in generation 
of “transcription factories” working either to maintain ES cell 
pluripotency or to drive them toward a cardiogenic fate.
Materials and methods
Culture and cardiac commitment of human pluripotent stem cells
Two HESC lines and one HiPSC line 11 (Maherali et al., 2008), using 
human dermal fibroblasts infected by lentivirus harboring the cDNAs   
encoding Oct4, Sox2, Lin 28, Klf4, and Nanog, were used throughout this 
study without any difference in results. HUES-24 and HUES-9 pOct4/GFP 
(a transgenic cell line generated using BAC) and iPS cell were cultured on 
mouse embryonic fibroblasts (MEFs) prepared from E14 mouse embryos as 
described previously (Tomescot et al. 2007). HESC were treated for 48 h 
with 10 ng/ml BMP2 in the presence of 1 µM SU5402, an FGF receptor 
inhibitor, in KOSR-DMEM. HESC (both HUES-9 and HUES-24) were used 
within no more than 10 passages (P28-P38). Cells are phenotyped every 
10 passages using anti-SSEA-3/4, TRA-1-60, and TRA-1-80 antibodies 
(Millipore).  Less  than  5%  of  cells  were  positive  for  SSEA-1  (Millipore). 
Karyotype was found normal and stable in the course of the experiments. EBs 
were generated from mock (GFP)–nucleofected or Oct4-iA–nucleofected in 
DMEM added with 20% FCS. Cells were let in suspension for 5 d to allow 
for their aggregation and then EBs were plated on gelatin-coated dishes 
for the next 3 wks. The blocking anti-BMP2 and anti-Wnt3a antibodies 
that a few BMP2-stimulated cells expressed both Sox17 and 
Mesp1/2, whereas most of them expressed only Sox17 or 
Mesp1/2. This differential expression of Sox17 and Mesp1/2 was 
observed in the same or neighboring cell colonies. To further 
quantify the phenomenon, we set up a high-content imaging   
assay. 32 wells and 50 fields per well were scanned for expression 
of GFP, Sox17, and Mesp1/2. Cells expressing GFP, Sox17, 
Mesp1/2 alone or expressing two or three markers were sepa-
rately scored. The Venn diagram (Fig. 4 F) first revealed that 
50% of cells responded to BMP2, as 44% did not express 
Sox17 and/or Mesp1/2. Half of responder cells (33% of total) 
expressed Sox17 and the other half (26% of total cells) expressed 
Mesp1/2. The diagram clearly shows that most of the cells ex-
pressed only Sox17, with many still highly GFP
+ or only Mesp2 
having lost GFP. A minority of the cells expressed Sox17 and 
Mesp1/2; almost no cell expressed the three markers. Although 
40–50% cells were nucleofected and overexpressed Oct4-iA, 
40–60% also expressed several markers including Mef2c and 
Nkx2.5, which together confer to the cells a cardiac fate (Fig. 1 G), 
further pointing to a robust paracrine effect of the latter. These 
findings suggest that the dual function of Oct4 is mediated by 
a paracrine phenomenon mediated by both BMP2 and Wnt3a. 
This claim is supported by three series of experiments: first, 
inhibitors or blocking antibodies, suggesting the presence in the 
medium of Sox17 expressing cells of both Wnt, known to be a 
target of Sox17 (Zorn et al., 1999) and BMP2, which cooperates 
with Wnt pathway (Crease et al., 1998; Kasai et al., 2005; Sumi 
et al., 2008); second, the BMP2 and Wnt signaling pathways 
were both activated in wells containing Oct4-iA–overexpressing 
cells, as revealed by intranuclear localization of both p-Smad1,5,8 
and -catenin in these cells together with the binding of Smad4 
to the Nkx2.5p and Tbx6p; and third, expression of BMP2 and 
Wnt3a mRNAs by Oct4-OEC. Indeed, both Wnt and BMP2 are 
well-known cardiogenic factors (Ménard et al., 2004; Liu et al., 
2007). Wnt exerts a cardiogenic action early on during embryo-
genesis to establish the primitive streak/mesendoderm and then 
BMP2 together with Wnt drive the cells toward the posterior 
primitive streak and mesoderm (Bakre et al., 2007; Sumi et al., 
2008). Furthermore, Wnt in the absence of Activin does not pro-
mote the hematopoietic lineage (Nostro et al., 2008) as well as 
Sox17 prevents the development of ectoderm (Séguin et al., 2008). 
Then, BMP2 takes over the cardiogenic task, Wnt becoming a 
cardiogenic inhibitor (Naito et al., 2006). The cardiogenic factors 
released by Oct4-induced Sox17
+ cells may exert their action in 
an autocrine, and/or in a paracrine manner on neighboring 
Sox17-negative cells driving them from an undifferentiated to a 
mesodermal cardiogenic fate. Using HCC imaging to moni-
tor expression of Sox17 and Mesp2 in BMP2-induced Oct4-
iA-OEC revealed that one third of Oct4-iA-OEC expressed 
Sox17 as expected from a direct targeting of Sox17 by the POU 
factor, whereas many cells expressing Mesp2 did not express any 
longer Oct4 or Sox17. This observation argues more for a para-
crine effect, although we cannot exclude a kinetic effect, cells 
going through a endo/mesendodermal stage (Sox17
+) and then 
to the cardiogenic mesoderm (Mesp1/2
+) turning off Sox17 
in line with the inhibitory effect of Mesp1/2 on Sox17 (Bondue 
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DNA constructs were nucleofected in HESCs, using Amaxa specific nucleo-
fector solution I, as recommended by the manufacturer.
Oct4-iA was amplified from RNA extracted from HESC as described 
in Lee et al. (2006) and subcloned in a pcDNA vector.
Cell immunofluorescence and imaging
Cell immunofluorescence was performed as described previously (Zeineddine 
et al., 2006). The anti-Sox17 antibody was from R&D Systems (Mab1924); 
anti-Nkx2.5 antibody from R&D Systems (MAB2444 clone 259416); anti-
Mef2c from Aviva; anti-CD31, CD45, and CD34 from Becton Dickinson; 
anti–phospho-Smad1/5/8 from Cell Signaling Technology; anti–-catenin 
from BD Biosciences; anti-sarcomeric actinin from Sigma-Aldrich; and anti-
cTnt from Abcam. Slides were mounted using Fluoromount-G (Electron 
Microscopy Science).
Cardiac TnT and -actinin fluorescent areas were measured in EBs 
using a thresholding and setting the cTnT and -actinin fluorescent areas as 
regions of interest (ROI) within whole EBs observed at 4x to measure the 
number of pixels within these ROIs with ImageJ software (National Institutes 
of Health, Bethesda, MD).
Images were acquired at room temperature with an epifluorescence 
microscope (AxioImager; Carl Zeiss, Inc.) using an Achroplan 10x objec-
tive (NA 0.25) (Fig. 1 C), a microscope (Axiostar; Carl Zeiss, Inc.) using 
an N-Achroplan objective (20x, NA 0.45) (Fig. 1 G), or a laser-scanning 
microscope (LSM510 Meta; Carl Zeiss, Inc.) using an Achroplan objective 
10x (NA 0.25) and Fluar 40x oil (NA 1.3) zoom 2x (Fig. 1 H), and visual-
ized without any processing by LSM browser software (Carl Zeiss, Inc.) or 
(Fig. 2) a microscope (Multiphoton Radiance 2000MP; Bio-Rad Laborato-
ries) attached to a Nikon Eclipse with a 10x PL-APO (NA 0.45) at room 
temperature and visualized with Bio-Rad Laboratories software and ImageJ 
without any processing.
FACS analysis
HESC were trypsinized and washed twice with PBS, filtered through a 70-µm 
mesh filter before FACS analysis using FACS Calibur (Becton Dickinson) 
and CELL QUEST software.
Protein immunoprecipitation and Western blots
END-2 cells were cultured in DMEM, supplemented with 10% FCS. Cells were 
nucleofected with Oct4-iA cDNA using the kit V (Amaxa). Cells were lysed in 
RIPA buffer. Co-Immunoprecipitation was performed in RIPA buffer and West-
ern blot analysis was conducted as reported previously (Pucéat et al., 1998). 
The anti-Oct4 antibodies used were from Santa Cruz Biotechnology, Inc. 
Sox2 and Oct4 Western blots were performed using the anti-Sox2 from Santa 
Cruz Biotechnology, Inc., and anti-Oct4 recognizing both Oct4-iA and -iB.
(MAB3552 and MAB1324, respectively; R&D Systems), used at a concen-
tration of 7.5 µg/ml medium, were added to mock or Oct4-iA–nucleofected 
cells for 2 d before RNA extraction and RT-Q-PCR of Tbx6, Mesp1, and 
Tbx5 genes.
RT-Q-PCR by SYBR green detection
RNA was extracted from ES cells using a QIAGEN or Zymo Research   
(Proteingene) kit or a Zymo Research RNA MicroPrep (Proteingene) for sin-
gles colonies. 1 µg of RNA was reverse-transcribed using the SuperScriptII 
reverse transcription (Invitrogen) and oligo(16)dT. Q-PCR was performed 
using a Light Cycler LC 1.5 or 480 (Roche) according to the manufacturer. 
Melting curves were used to determine the specificity of PCR products, con-
firmed using conventional gel electrophoresis and sequencing. Data were 
analyzed according to Pfaffl (2001). Primers specific for human genes are 
described in Tomescot et al. (2007) and are available on request.
Primers to amplify enhancer/promoter regions were: Sox17 pro-
moter: forward, 5-actttcacagtccaggaacggagt-3 and reverse 5-ggcttcctt-
ggagaaaggcaat-3 targeting a region within the 700-bp region upstream 
the transcription start site; Sox2: distal enhancer forward, 5-attagtct-
gctcttcctcggaatggttgg-3 and reverse, 5-tgatgcttgttaaaaacgcttcgctcc-3. 
Nkx2.5  promoter:  forward  5-cagtcttgggagctcaagact-3  and  reverse   
5-cagatccccaagcttactagc-3; Tbx6 promoter: forward 5-taacccgttcct-
gccccacct-3 and reverse 5-tccgcttgagctcccccttcc-3.
Chromatin immunoprecipitation (ChIP) assay
ChIP was performed according the Q2ChIP (Dahl and Collas, 2007) or 
Fast ChIP protocol (Nelson et al., 2006). Data were also confirmed using a 
standard ChIP procedure as described previously (Zeineddine et al., 2006). 
The antibodies used were anti-Oct4 (Santa Cruz Biotechnology, Inc.), anti-
Smad4 (Santa Cruz Biotechnology, Inc.) and anti-H3triMeK4, triMeK27, 
and acetylK9 (UBI). Q-PCR was used to amplify the DNA elements as de-
scribed above. Absolute enrichment was calculated assuming that at most 
1% of nucleosome was immunoprecipitated (Dahl and Collas, 2007). 
Genomic region was thus considered enriched if 10-ng immunoprecipita-
tion samples showed a greater enrichment when compared with 0.1 ng of 
input DNA. Data in all the text and figures are normalized to a control con-
dition (absolute enrichment set to one) and are thus representative of a rela-
tive enrichment in one experimental condition (BMP2 treatment or Oct4 
up-regulation) versus the control (non-treated cells or mock cells).
DNA constructs
Human Sox17 ShRNA targeted the following Sox17 cDNA sequence:   
5-gcaggtgaagcggctgaag-3. This was synthesized as a sense and antisense 
oligonucleotide, annealed and subcloned in pSuper vector (Ambion). The 
Figure 5.  The Sox17/Oct4 circuit is functional within a stem cell colony or “niche”. Oct4 and Sox17 work in combination to drive HuPSC toward a 
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Screening of immunostained cells by high content imaging
Immunofluorescence scan of BMP2-treated HUES-9 pOct4/GFP or Oct4iA 
nucleofected HESC stained with anti-Sox17 and Alexa 546–conjugated anti–
mouse IgG or anti-Mesp2 and anti-Alexa 680–conjugated anti–rabbit IgG 
antibodies or anti-Nkx2.5 and anti-Alexa 488–conjugated anti–rabbit 
IgG antibodies or anti-Mef2c and anti-Alexa 488–conjugated anti–mouse 
IgG antibodies: HESC were plated in 96-wells plates on MEF and treated 
or not with 10 ng/ml BMP2 and SU5402 for 4 d. Other cells were nucleo-
fected with Oct4iA cDNA and plated in Labtech. After immunostaining, the 
HC imaging 96-well plates (cells in PBS) were scanned with the Arrayscan 
(Cellomics Thermo Fisher Scientific attached to an inverted microscope 
[Carl Zeiss, Inc.] and using 20x N-Achroplan objective, NA 0.45, at room 
temperature) using the Cell Health Profiling Bioapplication. The fluores-
cence threshold was determined from the background obtained in non-
BMP2–stimulated cells or mock cells and set as a fixed threshold value to 
scan the wells of BMP2-treated cells or Oct4iA–nucleofected cells. In BMP2 
experiments, 50 fields/well and 32 wells were scanned giving a total of 
98,120 cells selected according the morphology, size, and the proximity 
of their nuclei (i.e., to discriminate HESC colonies from feeder cells). Differ-
ent types of events were scored using the cell feature parameters and the 
Boolean operators. The visualization of images and analysis were then 
performed using the vHCS software.
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Fig.  S1:  characterization  of  HUES-9  pOct4/GFP  clone.  Non-cardiac 
potential of differentiation of Oct4-OEC. KO of Sox2/Sox17 and con-
sequences on BMP2-induced gene expression. Fig. S2: paracrine action 
of Oct4-overexpressing cells. Fig. S3: Oct4-overexpressing cells activate 
Smad and -catenin pathways; The Oct4/Sox17 network is conserved 
in iPSCs. Online supplemental material is available at http://www.jcb 
.org/cgi/content/full/jcb.200901040/DC1.
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